[BCR::ABL1 阳性急性淋巴细胞白血病的分类及预后评估进展]
[The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia].
作者信息
Yan Y C, Wang C, Mi J Q, Wang J
机构信息
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):705-710. doi: 10.3760/cma.j.cn121090-20240315-00096.
Abstract
The application of tyrosine kinase inhibitors and targeted immunotherapy has revolutionized the therapeutic strategies and clinical outcome for BCR::ABL1-positive B-cell acute lymphoblastic leukemia (BCR::ABL1(+) B-ALL). The classification was updated successively by the World Health Organization and the International Consensus Classification in 2022. The risk stratification of this entity, for the first time, was modified by the National Comprehensive Cancer Network in 2023, both minimal residual disease assessment and IKZF1(plus) genotyping recognized as critical prognostic factors. These important updates would have significant implications for clinical management. Therefore, this review focused on the latest advances in the classification and prognostic evaluation of BCR::ABL1(+) B-ALL.
摘要
酪氨酸激酶抑制剂和靶向免疫疗法的应用彻底改变了BCR::ABL1阳性B细胞急性淋巴细胞白血病（BCR::ABL1(+) B-ALL）的治疗策略和临床结局。世界卫生组织和国际共识分类于2022年相继对其分类进行了更新。该疾病实体的风险分层在2023年首次由美国国立综合癌症网络进行了修订，微小残留病评估和IKZF1(plus)基因分型均被视为关键的预后因素。这些重要更新将对临床管理产生重大影响。因此，本综述聚焦于BCR::ABL1(+) B-ALL分类和预后评估的最新进展。
相似文献
1
[The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia].[BCR::ABL1 阳性急性淋巴细胞白血病的分类及预后评估进展]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):705-710. doi: 10.3760/cma.j.cn121090-20240315-00096.
2
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.基于免疫球蛋白/T 细胞受体和 BCR/ABL1 方法学，伊马替尼治疗后基于微小残留病灶预测费城染色体阳性急性淋巴细胞白血病的欧洲研究组的诱导治疗后治疗的费城染色体阳性急性淋巴细胞白血病的预测价值。
Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.
3
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.儿童BCR-ABL1样急性淋巴细胞白血病中的酪氨酸激酶融合基因。
Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.
4
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.伴有 CCDC88C-PDGFRB 融合的复发 BCR-ABL1 样急性淋巴细胞白血病患者中酪氨酸激酶抑制剂治疗的获益。
Int J Hematol. 2021 Feb;113(2):285-289. doi: 10.1007/s12185-020-03006-5. Epub 2020 Sep 19.
5
-like B-Acute Lymphoblastic Leukemia/Lymphoma: A Comprehensive Review.-B 急性淋巴细胞白血病/淋巴瘤：全面综述。
Arch Pathol Lab Med. 2020 Feb;144(2):150-155. doi: 10.5858/arpa.2019-0194-RA. Epub 2019 Oct 23.
6
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.BCR-ABL1 样特征和 IKZF1 缺失而非高 CRLF2 表达对儿童 B 细胞前体 ALL 具有独立预后价值。
Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.
7
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.数字液滴PCR用于评估成人Ph阳性急性淋巴细胞白血病中T315I BCR::ABL1 KD突变及微小残留病增加情况。
Leuk Lymphoma. 2023 Nov-Dec;64(11):1884-1887. doi: 10.1080/10428194.2023.2235450. Epub 2023 Jul 15.
8
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.根据微小残留病水平采用风险导向疗法治疗的BCR-ABL1样急性淋巴细胞白血病患儿的预后
J Clin Oncol. 2014 Sep 20;32(27):3012-20. doi: 10.1200/JCO.2014.55.4105.
9
A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.一种新型靶向 RNA-Seq .panel 鉴定出一组具有 BCR-ABL1 样特征的急性淋巴细胞白血病成人患者亚群。
Blood Cancer J. 2020 Apr 24;10(4):43. doi: 10.1038/s41408-020-0308-3.
10
Monitoring of childhood ALL using genomic breakpoints identifies a subgroup with CML-like biology.利用基因组断点监测儿童 ALL 可识别出具有 CML 样生物学特性的亚组。
Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22.
本文引用的文献
1
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.发育轨迹和协同的基因组事件定义了 BCR::ABL1 阳性 ALL 的分子亚型。
Blood. 2024 Apr 4;143(14):1391-1398. doi: 10.1182/blood.2023021752.
2
Association of deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia.急性淋巴细胞白血病造血干细胞移植后缺失与复发的关联。
Blood Cell Ther. 2023 Jul 21;6(3):80-86. doi: 10.31547/bct-2023-004. eCollection 2023 Aug 25.
3
Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood and High Hyperdiploid Acute Lymphoblastic Leukemia.光学基因组图谱鉴定儿童期和高超二倍体急性淋巴细胞白血病中的新型复发性结构改变。
Hemasphere. 2023 Jul 17;7(8):e925. doi: 10.1097/HS9.0000000000000925. eCollection 2023 Aug.
4
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.唐氏综合征和B细胞前体急性淋巴细胞白血病患儿中Ph样和IKZF1加状态的定义及预后价值
Hemasphere. 2023 May 26;7(6):e892. doi: 10.1097/HS9.0000000000000892. eCollection 2023 Jun.
5
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.Ph+ 阳性急性淋巴细胞白血病中超敏 NGS MRD 评估：与 BCR::ABL1 的 RT-PCR 检测的相关性及其预后意义。
Am J Hematol. 2023 Aug;98(8):1196-1203. doi: 10.1002/ajh.26949. Epub 2023 May 15.
6
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.四十余年来，MD 安德森对急性淋巴细胞白血病的研究与治疗的进展
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.
7
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.BCR::ABL1 阳性急性淋巴细胞白血病中的微小残留病：在典型急性淋巴细胞白血病和慢性粒细胞白血病样疾病中的不同意义。
Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6.
8
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.成人费城染色体阳性急性淋巴细胞白血病的治疗：从强化化疗联合到无化疗方案的回顾。
JAMA Oncol. 2022 Sep 1;8(9):1340-1348. doi: 10.1001/jamaoncol.2022.2398.
9
Impact of Deletions in the Prognosis of Childhood Acute Lymphoblastic Leukemia in Argentina.阿根廷儿童急性淋巴细胞白血病中缺失对预后的影响
Cancers (Basel). 2022 Jul 5;14(13):3283. doi: 10.3390/cancers14133283.
10
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
Zotero 插件